Rein Therapeutics (RNTX) Enterprise Value (2016 - 2025)
Rein Therapeutics (RNTX) has disclosed Enterprise Value for 10 consecutive years, with -$4.0 million as the latest value for Q3 2025.
- On a quarterly basis, Enterprise Value rose 77.1% to -$4.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$4.0 million, a 77.1% increase, with the full-year FY2024 number at -$12.9 million, up 25.8% from a year prior.
- Enterprise Value was -$4.0 million for Q3 2025 at Rein Therapeutics, up from -$5.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$3.6 million in Q4 2021 to a low of -$59.5 million in Q2 2021.
- A 5-year average of -$16.5 million and a median of -$12.1 million in 2023 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: plummeted 269.89% in 2021, then soared 87.18% in 2022.
- Rein Therapeutics' Enterprise Value stood at -$3.6 million in 2021, then plummeted by 43.97% to -$5.2 million in 2022, then plummeted by 232.21% to -$17.3 million in 2023, then rose by 25.8% to -$12.9 million in 2024, then skyrocketed by 68.53% to -$4.0 million in 2025.
- Per Business Quant, the three most recent readings for RNTX's Enterprise Value are -$4.0 million (Q3 2025), -$5.7 million (Q2 2025), and -$7.4 million (Q1 2025).